Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 84.83% year-over-year to $5.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 84.83% decrease from a year earlier, with the FY2025 full-year figure at $58.6 million, down 84.31% from the prior year.
• Accumulated Expenses retreated to $5.4 million in Q1 2026 per SRPT's latest filing, from $58.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $383.7 million in Q2 2022 and bottomed at $3.2 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $50.0 million (2024), against an average of $114.6 million.
• Across the five-year window, Accumulated Expenses jumped 10759.65% in 2023 and tumbled 93.9% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $5.0 million in 2022, then soared by 1488.62% to $78.7 million in 2023, then jumped by 374.41% to $373.5 million in 2024, then sank by 84.31% to $58.6 million in 2025, then tumbled by 90.86% to $5.4 million in 2026.
• Per Business Quant, the three latest SRPT Accumulated Expenses figures stand at $5.4 million (Q1 2026), $58.6 million (Q4 2025), and $3.5 million (Q3 2025).